A large pharmaceutical company based in the US is looking to make strategic investments in therapeutic assets. The firm uses a variety of partnership structures on a case by case basis, but typically focuses on acquiring or in-licensing assets. The firm is interested in partnering with biotech companies worldwide.
The firm’s partnering is currently focused on oncology (including both solid tumors and liquid tumors), liver diseases (particularly NASH and fibrosis), inflammatory diseases, and cures for infectious disease (particularly cures for hepatitis B and HIV; vaccines will also be considered). The firm is interested in both small molecule and biologic technologies, but is generally not interested in cell therapies.
While the firm may consider assets at any stage, the firm typically works with companies at the late phase I-early phase II stage, and in the oncology field prefers that companies have some human proof of concept data. Partnerships in the infectious disease field may be formed at an earlier stage, prior to human clinical trials.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Next Phase Newsletter 
Leave a comment